ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Adjusting Dosing to Increase Efficacy of Cetuximab in Head and Neck Cancer

Joseph Ciccolini, PhD
Published Online:2:03 PM, Mon April 10, 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.